An assessment of gynecological cytology screening practices among health care providers nationwide
- PMID: 25927148
- DOI: 10.5858/arpa.2013-0620-OA
An assessment of gynecological cytology screening practices among health care providers nationwide
Abstract
Context: The Michigan Public Health Institute and the Michigan Cancer Consortium's Cervical Cancer Committee conducted a national survey of health care providers, thanks to funding from the Centers for Disease Control Cooperative Agreement 5U47CI000743-02. Papanicolaou test screening practices were examined, emphasizing the relationship between clinical and laboratory practices. This survey found differing screening practices among providers of women's health care.
Objectives: To collect information from family medicine practitioners, women's nurse practitioners, obstetricians and gynecologists, and certified nurse-midwives on Papanicolaou and human papillomavirus testing; to discuss how those practices align with current cytology screening and follow-up recommendations from professional organizations (US Preventive Services Task Force, American Cancer Society, American College of Obstetricians and Gynecologists, and American Society for Colposcopy, and Cervical Pathology); and ultimately, to make recommendations aimed at standardizing practice performance.
Design: This survey was conducted in part to examine clinicians' practices and their perceptions of laboratory performance, to evaluate items that are known to enhance quality of care, and to examine factors that may prohibit universal implementation of best standards of care. The survey used a self-administered questionnaire, distributed to 9366 clinicians, with 1601 (17.1%) completed surveys.
Results: This assessment shows a clear lack of consensus among practitioners in performing Papanicolaou testing. It demonstrates how differently patients are tested, based on the providers' screening practices, and demonstrates specific cervical cancer screening practice disparities between and among the 4 provider groups, both in Papanicolaou testing and in the use of human papillomavirus testing.
Conclusion: A unified mandate for screening is needed to standardize screening practices.
Similar articles
-
Specialty differences in primary care physician reports of papanicolaou test screening practices: a national survey, 2006 to 2007.Ann Intern Med. 2009 Nov 3;151(9):602-11. doi: 10.7326/0003-4819-151-9-200911030-00005. Ann Intern Med. 2009. PMID: 19884621
-
Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).Cancer. 2007 Sep 1;110(5):1024-32. doi: 10.1002/cncr.22875. Cancer. 2007. PMID: 17628488
-
Current practice patterns in cervical cancer screening in Indiana.Am J Obstet Gynecol. 2014 Mar;210(3):265.e1-8. doi: 10.1016/j.ajog.2014.01.001. Epub 2014 Jan 8. Am J Obstet Gynecol. 2014. PMID: 24412744
-
Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening.CA Cancer J Clin. 2010 Mar-Apr;60(2):99-119. doi: 10.3322/caac.20063. CA Cancer J Clin. 2010. PMID: 20228384 Review.
-
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.Obstet Gynecol. 2004 Feb;103(2):304-9. doi: 10.1097/01.AOG.0000109426.82624.f8. Obstet Gynecol. 2004. PMID: 14754700 Review.
Cited by
-
Assessment of US Preventive Services Task Force Guideline-Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019.JAMA Netw Open. 2022 Jan 4;5(1):e2143582. doi: 10.1001/jamanetworkopen.2021.43582. JAMA Netw Open. 2022. PMID: 35040970 Free PMC article.
-
Obstetrician-gynecologists' practice patterns regarding HPV testing in cervical cancer screening in Turkey.Turk J Obstet Gynecol. 2021 Mar 12;18(1):15-22. doi: 10.4274/tjod.galenos.2021.36418. Turk J Obstet Gynecol. 2021. PMID: 33715328 Free PMC article.
